简介：AbstractBackground:The Tubridge™ flow diverter (TFD) was recently developed in China; however, its safety and efficacy in treating large cavernous carotid artery aneurysms (LCCAs) are unclear. Our objective was to evaluate the safety and efficacy of the TFD in patients receiving TFDs to treat LCCAs (10-25 mm).Methods:Between June 2013 and May 2014, seven patients with LCCAs were enrolled in our study, and all seven patients underwent TFD implantation combined with coils.Results:Angiographic follow-up images were available for all seven patients at a median of 57.5 ± 16.7 (range, 6-69) months. Seven patients obtained favorable angiographic results defined as O'Kelly-Marotta Scale C and D. Clinical follow-up data were available for all seven patients at a median of 73.32 ± 3.6 (range, 66-78) months. No patients developed new neurological deficits. Six patients achieved a modified Rankin scale score of 0, and diplopia improved in the remaining patient.Conclusions:The results were excellent for the aneurysms treated with TFDs in our patients with LCCAs. TFDs are feasible for the treatment of LCCAs, but a multicenter, controlled clinical trial is needed to evaluate the long-term safety and efficacy of the TFD to treat LCCAs.

简介：摘要目的观察国产血流导向装置Tubridge治疗颅内复杂动脉瘤的短期疗效及并发症，总结Tubridge治疗颅内复杂动脉瘤的适应证及经验。方法选择中国科技大学附属第一医院神经外科自2020年1月至2020年12月应用血流导向装置Tubridge治疗的31例颅内复杂动脉瘤患者进入研究。术后即刻采用Raymond分级评估动脉瘤的栓塞程度。术后6个月采用改良Rankin量表(mRS)评分评估患者预后。术后6个月、12个月患者行DSA复查以明确动脉瘤的栓塞情况。结果31例患者共37个动脉瘤。37个动脉瘤共置入32枚Turbridge，均成功输送并释放，其中13个瘤体填塞弹簧圈(术后即刻DSA检查显示Raymond分级Ⅰ级8个，Raymond分级Ⅱ级2个，Raymond分级Ⅲ级3个)，24个瘤体未填弹簧圈。1例患者术后发生缺血性并发症，无出血性并发症发生、无死亡患者。随访时31例患者均预后良好。术后6个月24例(77.4%)患者行DSA复查显示动脉瘤完全闭塞17例(70.8%)。术后12个月25例患者行DSA复查显示动脉瘤完全闭塞19例(76%)。结论应用新型国产血流导向装置Tubridge治疗颅内复杂动脉瘤成功率高、围手术期并发症少，安全性较高，患者预后良好。

简介：摘要目的探讨使用Tubridge血流导向装置治疗支架辅助栓塞后复发性颈内动脉血泡样动脉瘤的安全性及有效性。方法回顾性连续纳入2018年6月至2021年4月期间海军军医大学附属长海医院神经外科采用Tubridge血流导向装置治疗的复发性颈内动脉血泡样动脉瘤患者，分析围手术期安全性、术后即刻及随访结果。结果共纳入6例既往支架辅助弹簧圈栓塞后复发的颈内动脉血泡样动脉瘤患者。首次支架辅助栓塞治疗至置入Tubridge的时间间隔为14 ~90 d。4例患者采用单纯Tubridge置入，另外2例填塞弹簧圈后再置入Tubridge。围手术期无并发症，临床随访5~36个月，无再出血。5例患者接受血管造影随访1~3个月，动脉瘤均完全消失。结论Tubridge血流导向装置治疗复发性血泡样动脉瘤安全且有效。